Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
Go back to Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe| ARROWHEAD RESEARCH (NASDAQ: ARWR) | Delayed: 81.80 -0.02 (0.02%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $81.82 | 52 Week High | $8.22 | |||
| Open | $83.00 | 52 Week Low | $3.07 | |||
| Day High | $84.00 | P/E | N/A | |||
| Day Low | $81.68 | EPS | $-1.30 | |||
| Volume | 732,984 | |||||
